Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v2.4.1.9
Consolidated Balance Sheets (USD $)
Feb. 28, 2015
Nov. 30, 2014
Current Assets    
Cash and cash equivalents $ 3,550,243us-gaap_CashAndCashEquivalentsAtCarryingValue $ 3,279,267us-gaap_CashAndCashEquivalentsAtCarryingValue
Restricted cash 204,197us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue 204,141us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue
Marketable securities 98,261us-gaap_MarketableSecuritiesCurrent 102,674us-gaap_MarketableSecuritiesCurrent
Accounts receivable (net of allowance for doubtful accounts of $2,032,416 and $1,976,966, respectively ) 4,200,003us-gaap_AccountsReceivableNetCurrent 4,071,997us-gaap_AccountsReceivableNetCurrent
Prepaid expenses 664,674us-gaap_PrepaidExpenseCurrent 710,754us-gaap_PrepaidExpenseCurrent
Other current assets 129,626us-gaap_OtherAssetsCurrent 123,126us-gaap_OtherAssetsCurrent
Total current assets 8,847,004us-gaap_AssetsCurrent 8,491,959us-gaap_AssetsCurrent
Property and Equipment-net 918,190us-gaap_PropertyPlantAndEquipmentNet 953,415us-gaap_PropertyPlantAndEquipmentNet
Other Assets    
Investment in Saneron CCEL Therapeutics, Inc. 684,000us-gaap_EquityMethodInvestments 684,000us-gaap_EquityMethodInvestments
Deposits and other assets, net 70,171ccel_DepositsAndOtherAssets 80,212ccel_DepositsAndOtherAssets
Total other assets 754,171us-gaap_OtherAssetsNoncurrent 764,212us-gaap_OtherAssetsNoncurrent
Total assets 10,519,365us-gaap_Assets 10,209,586us-gaap_Assets
Current Liabilities    
Accounts payable 1,335,709us-gaap_AccountsPayableCurrent 992,910us-gaap_AccountsPayableCurrent
Accrued expenses 907,075us-gaap_AccruedLiabilitiesCurrent 1,471,699us-gaap_AccruedLiabilitiesCurrent
Deferred revenue 6,460,146us-gaap_DeferredRevenueCurrent 6,662,552us-gaap_DeferredRevenueCurrent
Total current liabilities 8,702,930us-gaap_LiabilitiesCurrent 9,127,161us-gaap_LiabilitiesCurrent
Other Liabilities    
Deferred revenue, net of current portion 9,797,209us-gaap_DeferredRevenueNoncurrent 9,509,088us-gaap_DeferredRevenueNoncurrent
Long-term liability - revenue sharing agreements 2,300,000us-gaap_LongTermDebtNoncurrent 2,300,000us-gaap_LongTermDebtNoncurrent
Total other liabilities 12,097,209us-gaap_OtherLiabilitiesNoncurrent 11,809,088us-gaap_OtherLiabilitiesNoncurrent
Commitments and contingencies (Note 6)      
Stockholders' Deficit    
Preferred stock ($.01 par value, 500,000 authorized and none issued and outstanding), and Series A Junior participating preferred stock ($.01 par value, 20,000 authorized and none issued and outstanding)      
Common stock ($.01 par value, 20,000,000 authorized; 12,225,340 issued and 9,993,808 outstanding as of February 28, 2015 and 11,921,285 issued and 9,706,174 outstanding as of November 30, 2014) 119,213us-gaap_CommonStockValue 119,213us-gaap_CommonStockValue
Additional paid-in capital 28,040,867us-gaap_AdditionalPaidInCapitalCommonStock 27,842,106us-gaap_AdditionalPaidInCapitalCommonStock
Treasury stock, at cost (5,151,690)us-gaap_TreasuryStockValue (5,112,648)us-gaap_TreasuryStockValue
Accumulated deficit (33,289,164)us-gaap_RetainedEarningsAccumulatedDeficit (33,575,334)us-gaap_RetainedEarningsAccumulatedDeficit
Total stockholders' deficit (10,280,774)us-gaap_StockholdersEquity (10,726,663)us-gaap_StockholdersEquity
Total liabilities and stockholders' deficit $ 10,519,365us-gaap_LiabilitiesAndStockholdersEquity $ 10,209,586us-gaap_LiabilitiesAndStockholdersEquity